Markets
Superstars
Analyst Estimates
Alerts
Screeners
Subscribe
Calendar
ETFs
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
Explore
FAQs
Widgets
More
Search stocks
IND
USA
USA
USA
×
Close
IND
USA
Stocks
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Nektar Therapeutics
Swot
Nektar Therapeutics SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Nektar Therapeutics has 8 Strengths, 14 Weaknesses, 0 Opportunities and 3 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(8)
Weakness
(14)
Opportunity
(0)
Threats
(3)
Others
(1)
Relative Outperformance versus Industry over 1 Week
Significant (over 30%) distance from 52 week high
Relative Outperformance versus Industry over 1 Year
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
Stock with Low PE (PE < = 10)
RSI indicating price strength
Stocks with Quarter Change % less than Industry
Momentum Trap (DVM)
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Low DVM Stocks - Stocks to Exercise Caution On
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Risky Value (DVM)
Low durability companies
Inefficient use of shareholder funds - ROE declining in the last 2 years
Highest fall from 52 Week High
Top Losers
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter
Mutual Funds Decreased Shareholding in Past Month
MFs decreased their shareholding last quarter
Institutions decreased their shareholding last quarter
Promoters increasing shareholding QoQ
